Nutrigenomics Market Summary

• The global nutrigenomics market was valued at USD 1.0 billion in 2025 and is projected to reach USD 4.3 billion by 2034.
• The market is expected to expand at a CAGR of 17.5% during the forecast period 2026-2034, supported by growing adoption of personalized nutrition and preventive healthcare, advancements in DNA sequencing and metabolomics that lower the cost and complexity of genetic testing, increasing integration of artificial intelligence and digital health platforms into diet planning, and continued restructuring and consolidation among direct-to-consumer genetic testing companies.
• By product type, reagents and kits dominated the nutrigenomics market in 2025, while services represented the fastest-growing product category.
• By distribution channel, hospitals and clinics dominated the nutrigenomics market with an approximately 56% share in 2025.
• North America accounted for the largest share of the nutrigenomics market at approximately 41% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034, at an estimated CAGR of 18.2%.

Nutrigenomics is the study of how an individual's genetic makeup influences their response to nutrients and dietary components, and encompasses the DNA-based testing products and services used to generate personalized nutrition recommendations. The scope encompasses genetic testing reagents and kits and interpretation services from Nutrigenomix, a genetics-based nutrition testing company serving healthcare professionals; consumer genomics and research platforms, including the Personal Genome Service and research operations of 23andMe, now operated by the nonprofit TTAM Research Institute following its 2025 acquisition of the company's assets out of bankruptcy; clinical nutrigenomics and functional testing panels from Genova Diagnostics and Viome; and sequencing platforms from Illumina that underpin much of the genetic testing infrastructure used across the nutrigenomics industry. The market spans obesity and weight management, diabetes and metabolic health, cardiovascular disease, and cancer risk applications, delivered through hospital and clinic-based testing programs and direct-to-consumer online platforms.

Nutrigenomics Market Key Growth Drivers

• Growing adoption of personalized nutrition and preventive healthcare, as consumers and healthcare providers increasingly seek individualized dietary strategies over one-size-fits-all nutrition guidelines.
• Advancements in DNA sequencing and metabolomics that continue to lower the cost and complexity of genetic testing, expanding the addressable population for nutrigenomics-based products and services.
• Increasing integration of artificial intelligence and big data analytics into diet planning platforms, improving the accuracy and personalization of dietary recommendations derived from genetic testing results.
• Expansion of nutrigenomic testing services across hospitals and clinics, which dominate the market's distribution channel due to established provider trust, integrated sample collection, and professional interpretation of results.
• Continued restructuring and consolidation among direct-to-consumer genetic testing companies, exemplified by TTAM Research Institute's 2025 acquisition of 23andMe's Personal Genome Service and research operations out of bankruptcy, which preserved continuity of a major consumer genomics platform.
• Growing digital health platform integration, exemplified by Lifesum's acquisition of LYKON to combine genetic-based nutrition and biomarker testing with personalized dietary recommendations within a single consumer wellness platform.
• Rising clinical research interest in gene-diet interactions for specific conditions, exemplified by a 2024 Oregon Health and Science University clinical trial examining whether older adults with a genetic predisposition to Alzheimer's disease respond differently to fish oil supplementation.

Key Companies in Nutrigenomics Market

The leading participants in the nutrigenomics market include the following:

• TTAM Research Institute (23andMe)
• Nutrigenomix Inc.
• Illumina, Inc.
• Genova Diagnostics, Inc.
• Viome Inc.
• Pathway Genomics Corporation
• 3X4 Genetics
• Vitagene, Inc.
• Fagron Genomics S.L.
• GenePlanet d.o.o.

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

Nutrigenomics Market Size

The following table summarizes the headline market metrics for the global nutrigenomics market across the base year and the forecast horizon.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Nutrigenomics Market

Market Drivers

Growing Adoption of Personalized Nutrition and Preventive Healthcare

The foundational driver of the nutrigenomics market is the growing adoption of personalized nutrition and preventive healthcare, reflecting a broader cultural shift away from generalized dietary guidelines toward individualized nutrition strategies informed by genetic testing. Consumers are increasingly seeking actionable insights derived from their genetic data to guide dietary choices related to macronutrient metabolism, vitamin and mineral processing, and food sensitivities. As awareness of the relationship between genetics, nutrition, and long-term health outcomes continues to grow, demand for nutrigenomics-based testing products and services expands correspondingly across both clinical and consumer settings throughout the forecast period.

Advancements in DNA Sequencing and Metabolomics

Advancements in DNA sequencing and metabolomics technology continue to lower the cost and complexity of genetic testing, expanding the addressable population for nutrigenomics-based products and services. Sequencing platforms from Illumina and other genomics technology providers have driven down the per-sample cost of genetic analysis over the past decade, making population-scale nutrigenomics testing increasingly commercially viable. As sequencing costs continue to decline and as metabolomic profiling technology continues to mature, the technical and economic barriers that have historically limited nutrigenomics testing accessibility continue to erode, sustaining demand growth across the forecast period.

Increasing Integration of AI and Big Data in Diet Planning

The increasing integration of artificial intelligence and big data analytics into diet planning platforms is improving the accuracy and personalization of dietary recommendations derived from genetic testing results. Companies are increasingly embedding digital health platforms, mobile applications, and cloud-based analytics tools into their nutrigenomics offerings, providing consumers with real-time insights and continuously refined, customized wellness programs rather than a single static report. As artificial intelligence and digital health platform integration continues to mature, the practical utility and consumer engagement value of nutrigenomics testing services continues to improve, sustaining adoption across the forecast period.

Expansion of Testing Services Across Hospitals and Clinics

The expansion of nutrigenomic testing services across hospitals and clinics reflects the high level of consumer and provider trust placed in established healthcare settings for genetic testing and dietary counseling. Hospitals and clinics offer integrated nutrigenomics testing services encompassing on-site sample collection, laboratory processing, and professional interpretation of results by trained healthcare providers, an integrated care model that has driven this channel's dominant market position. As the number of diagnostic centers within hospital networks continues to grow and as healthcare professional awareness of personalized nutrition continues to rise, the hospital and clinic distribution channel is expected to retain its leading position across the forecast period.

Restructuring and Consolidation Among Direct-to-Consumer Genetic Testing Companies

Continued restructuring and consolidation among direct-to-consumer genetic testing companies is reshaping the competitive landscape of the broader consumer genomics ecosystem that underpins much of the nutrigenomics market. 23andMe filed for Chapter 11 bankruptcy in March 2025 following a period of declining consumer demand and the lasting reputational impact of a 2023 data breach, and its assets, including its Personal Genome Service and research operations, were subsequently acquired by TTAM Research Institute, a nonprofit public benefit corporation founded and led by 23andMe co-founder Anne Wojcicki, for USD 305 million in a transaction that closed in July 2025. This restructuring preserved continuity of a major consumer genomics platform under a nonprofit governance structure explicitly focused on data privacy and continued genetic research. As the direct-to-consumer genetic testing sector continues to consolidate and as surviving and reorganized companies rebuild consumer trust, the underlying consumer genomics infrastructure supporting nutrigenomics testing continues to stabilize across the forecast period.

Growing Digital Health Platform Integration

Growing digital health platform integration reflects the strategic logic of combining genetic testing capability with the broader consumer engagement and dietary tracking infrastructure of established digital health and wellness applications. Lifesum's acquisition of LYKON exemplifies this strategy, combining LYKON's genetic-based nutrition and biomarker testing expertise with Lifesum's existing digital health platform to create a more comprehensive, science-driven approach to personalized wellness that integrates genetic insights directly into everyday dietary tracking and recommendation tools. As digital health platforms continue to acquire or partner with specialized genetic testing providers, the practical reach and consumer accessibility of nutrigenomics-based recommendations continues to expand across the forecast period.

Rising Clinical Research Interest in Gene-Diet Interactions

Rising clinical research interest in gene-diet interactions for specific health conditions is expanding the clinical evidence base supporting nutrigenomics-informed dietary intervention. A 2024 clinical trial at Oregon Health and Science University examined whether a subset of older adults carrying a genetic predisposition to Alzheimer's disease respond differently to fish oil supplementation, reflecting a broader research trend toward identifying genetically defined subpopulations that may benefit differentially from specific nutritional interventions. As this clinical evidence base continues to expand across additional conditions and genetic variants, the scientific credibility and clinical utility of nutrigenomics testing continues to strengthen, supporting adoption across both clinical and consumer settings throughout the forecast period.

Market Restraints

The nutrigenomics market faces several interrelated restraints that temper its growth. Limited consumer and healthcare provider awareness of nutrigenomics as a distinct discipline, combined with continued dependence on general dietary guidelines in mainstream clinical practice, constrains broader adoption of genetically informed personalized nutrition recommendations. The relatively high cost of genomic analysis, even as sequencing costs continue to decline, remains a barrier for price-sensitive consumers considering discretionary, largely out-of-pocket nutrigenomics testing services. Fragmented nutrition and healthcare data, with genetic testing results, dietary tracking data, and clinical health records often housed in separate, non-interoperable systems, limits the practical, longitudinal utility of nutrigenomics insights for both consumers and healthcare providers. Data privacy and security concerns, heightened by high-profile incidents such as 23andMe's 2023 data breach and subsequent 2025 bankruptcy, continue to affect consumer trust in direct-to-consumer genetic testing companies more broadly. The scientific evidence base linking specific genetic variants to actionable, clinically meaningful dietary recommendations remains incomplete for many marketed nutrigenomics panels, creating a gap between commercially available testing claims and the depth of peer-reviewed clinical validation for some applications. Together, these factors moderate the pace of adoption and require nutrigenomics companies to demonstrate scientific rigor, data security, and clear consumer value to sustain growth.

Nutrigenomics Market Segment Analysis

The global nutrigenomics market is segmented by product type (reagents and kits and services), by application (obesity and weight management, diabetes and metabolic health, cardiovascular disease, cancer risk, and others), by distribution channel (hospitals and clinics, direct-to-consumer online platforms, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World). 

By Product Type

Dominant Subsegment: Reagents and Kits.

The reagents and kits category is expected to dominate the market. Reagents and kits, encompassing the sample collection and genetic analysis materials used across nutrigenomics testing panels, are the leading product category because they represent the foundational, recurring consumable component of every nutrigenomics test performed, whether administered in a clinical setting or through a direct-to-consumer testing kit. The dominance of the segment reflects the transactional, per-test nature of nutrigenomics testing revenue and the breadth of testing panel providers, including Nutrigenomix, 3X4 Genetics, and Vitagene, that supply reagents and kits to healthcare providers and consumers. Services, including genetic counseling, results interpretation, and ongoing personalized nutrition coaching, represented the fastest-growing product category, reflecting the growing consumer and provider demand for actionable guidance that extends beyond a static genetic test report.

By Distribution Channel

Dominant Subsegment: Hospitals and Clinics.

The hospitals and clinics category is expected to dominate the market. The segment accounted for approximately 56% share of the nutrigenomics market in 2025. Hospitals and clinics are the leading distribution channel because of the high level of consumer trust placed in established healthcare providers for genetic testing and dietary counseling, and because hospitals and clinics offer integrated nutrigenomics testing services encompassing on-site sample collection, laboratory processing, and professional interpretation of results by trained healthcare providers. The dominance of the segment reflects the increasing number of diagnostic centers within hospital networks and rising awareness among healthcare professionals about the clinical value of personalized nutrition. Direct-to-consumer online platforms represent a substantial and evolving channel, particularly following the restructuring of major consumer genomics companies such as 23andMe under new nonprofit ownership.

Nutrigenomics Market Region Analysis

Dominant Region: North America

North America accounted for approximately 41% of the global nutrigenomics market in 2025, representing the highest regional market share globally. The leadership of the region reflects high consumer awareness of genetic testing, advanced healthcare infrastructure, and strong adoption of personalized wellness products, alongside the concentration of leading companies including Illumina, Genova Diagnostics, Viome, and TTAM Research Institute's 23andMe. The United States is the largest national market, supported by an established direct-to-consumer genetic testing culture, sustained biotechnology investment, and a large base of hospitals and clinics offering integrated nutrigenomics testing services. The concentration of vendors, consumer awareness, and healthcare infrastructure reinforce the position of North America as the largest regional market across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034, at an estimated 18.2%. The region is expanding genomics research infrastructure and increasing consumer awareness of personalized nutrition, supported by growing biotechnology investment and rising disposable income across major markets. China, Japan, and India are the principal national markets, supported by expanding healthcare infrastructure, growing domestic genetic testing capacity, and increasing government investment in genomics research programs. As consumer awareness of nutrigenomics continues to grow and as domestic testing infrastructure continues to expand, Asia-Pacific is positioned as the fastest-growing regional market across the forecast period.

Regional Commentary

North America

North America leads the market, supported by high consumer awareness, advanced healthcare infrastructure, and the concentration of leading companies. The United States dominates the region through its established direct-to-consumer genetic testing culture and concentration of genomics companies.

Europe

Europe is a substantial market shaped by strong healthcare infrastructure and the presence of leading companies including Fagron Genomics and GenePlanet. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and the region continues to see growing integration of nutrigenomics testing with digital health platforms.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by expanding genomics research infrastructure, rising consumer awareness of personalized nutrition, and growing biotechnology investment across China, Japan, and India.

Rest of World

The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as healthcare infrastructure and consumer awareness of genetic testing expand, though adoption of nutrigenomics testing remains concentrated in leading urban centers and private healthcare systems.

Nutrigenomics Market Competitive Landscape

The global nutrigenomics market is classified as Fragmented. Control over the market is increasingly concentrated among a handful of innovative biotech firms, digital health startups, and established consumer health companies that possess advanced genomic capabilities and robust data analytics infrastructure, including Nutrigenomix, TTAM Research Institute's 23andMe, and Viome, while large pharmaceutical and healthcare corporations are also entering the space through strategic acquisitions and collaborations. Competition centers on breadth of genetic testing panel coverage, depth of AI-driven interpretation and personalization capability, distribution channel reach across hospitals, clinics, and direct-to-consumer platforms, and consumer trust in data privacy and security. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Fragmented, with no single company holding a dominant global share, reflecting the diversity of testing panel providers, consumer genomics platforms, and digital health integration models across the industry.
• Leading players: Nutrigenomix leads in healthcare professional-oriented genetic testing panels for personalized nutrition counseling; TTAM Research Institute leads in consumer genomics scale through its 23andMe Personal Genome Service and research operations following its 2025 bankruptcy acquisition; and Illumina leads in the sequencing infrastructure underlying much of the industry's genetic testing capability.
• Geographic reach: Illumina and TTAM Research Institute's 23andMe operate global or multinational commercial organizations, while specialist vendors including Fagron Genomics, GenePlanet, and 3X4 Genetics maintain more concentrated footprints centered on specific regions.
• Product portfolio strength: Competitive advantage rests on the breadth of genetic variant coverage across nutrition-relevant pathways, and on the integration of testing results with digital health platforms, mobile applications, and ongoing personalized nutrition coaching services.
• Pipeline strength: Development is concentrated in expanded genetic panel coverage for emerging application areas such as cancer risk and cardiovascular disease, AI-driven interpretation algorithms, and integration with broader digital health and wellness platforms.
• Strategic partnerships: Collaboration spans digital health platform integration partnerships, exemplified by Lifesum's acquisition of LYKON, and clinical research collaborations, exemplified by the Oregon Health and Science University clinical trial examining APOE genetic status and fish oil supplementation response.
• M&A activity: Consolidation has shaped the field, exemplified by TTAM Research Institute's USD 305 million acquisition of 23andMe's Personal Genome Service and research operations out of Chapter 11 bankruptcy in 2025, and Lifesum's acquisition of LYKON to integrate genetic-based nutrition testing into its digital health platform.
• Innovation focus: Innovation is concentrated in AI-driven personalization algorithms, expanded genetic panel coverage for chronic disease risk applications, and integration of genetic testing with continuous digital health tracking and coaching platforms.
• Regulatory standing: Compliance with clinical laboratory and genetic testing regulatory requirements, and adherence to data privacy and security standards following heightened scrutiny after high-profile incidents such as 23andMe's 2023 data breach, are decisive competitive credentials across this consumer-facing market.

Nutrigenomics Market Recent Developmental Activities

• In July 2025, TTAM Research Institute completed its acquisition of the Personal Genome Service and research operations of 23andMe for USD 305 million, following a bankruptcy auction in which it outbid Regeneron Pharmaceuticals' earlier offer. Strategic significance: the acquisition preserved continuity of a major consumer genomics platform under nonprofit ownership explicitly focused on data privacy and continued genetic research.
• In March 2025, 23andMe filed for Chapter 11 bankruptcy protection following a period of declining consumer demand and the lasting reputational impact of its 2023 data breach, with co-founder Anne Wojcicki resigning as CEO. Strategic significance: the bankruptcy filing marked a significant restructuring event for one of the largest consumer genomics platforms underpinning the broader nutrigenomics ecosystem.
• In January 2025, 23andMe launched Discover23, a research offering enabling authorized collaborators to securely access genome-wide association study data across more than 1,000 disease and condition cohorts through a Trusted Research Environment developed by Lifebit. Strategic significance: the launch expanded 23andMe's research services offering shortly before its subsequent bankruptcy filing.
• In January 2025, LifeVantage Corporation announced the global launch of its MindBody GLP-1 System, a wellness product designed to activate optimal health processes at the cellular level. Strategic significance: the launch reflected continued innovation at the intersection of genetics-informed wellness products and broader metabolic health trends.
• In November 2024, ProPhase Labs launched DNA Complete, a wholly owned subsidiary providing direct-to-consumer whole genome sequencing services offering in-depth insights into health, wellness, and ancestry. Strategic significance: the launch expanded ProPhase Labs' presence in the consumer genomics market amid broader industry restructuring.
• In August 2024, a clinical trial at Oregon Health and Science University examined whether a subset of older adults with a genetic predisposition to Alzheimer's disease respond differently to fish oil supplementation. Strategic significance: the study contributed to the expanding clinical evidence base supporting genetically informed dietary intervention for specific conditions.
• Lifesum acquired LYKON to integrate genetic-based nutrition and biomarker testing expertise into its digital health platform, creating a more comprehensive, science-driven approach to personalized wellness. Strategic significance: the acquisition exemplified the broader industry trend toward combining genetic testing capability with established digital health and dietary tracking infrastructure.

Nutrigenomics Market Segmentation

Nutrigenomics Market Assessment by Product Type

• Reagents and Kits
• Services

Nutrigenomics Market Assessment by Application

• Obesity and Weight Management
• Diabetes and Metabolic Health
• Cardiovascular Disease
• Cancer Risk
• Others

Nutrigenomics Market Assessment by Distribution Channel

• Hospitals and Clinics
• Direct-to-Consumer Online Platforms
• Others

Nutrigenomics Market Assessment by Geography

• North America

• United States Nutrigenomics Market Size in USD million (2023-2034)
• Canada Nutrigenomics Market Size in USD million (2023-2034)
• Mexico Nutrigenomics Market Size in USD million (2023-2034)

• Europe

• Germany Nutrigenomics Market Size in USD million (2023-2034)
• United Kingdom Nutrigenomics Market Size in USD million (2023-2034)
• France Nutrigenomics Market Size in USD million (2023-2034)
• Italy Nutrigenomics Market Size in USD million (2023-2034)
• Spain Nutrigenomics Market Size in USD million (2023-2034)
• Rest of Europe Nutrigenomics Market Size in USD million (2023-2034)

• Asia-Pacific

• China Nutrigenomics Market Size in USD million (2023-2034)
• Japan Nutrigenomics Market Size in USD million (2023-2034)
• India Nutrigenomics Market Size in USD million (2023-2034)
• Australia Nutrigenomics Market Size in USD million (2023-2034)
• South Korea Nutrigenomics Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Nutrigenomics Market Size in USD million (2023-2034)

• Rest of the World

• Middle East Nutrigenomics Market Size in USD million (2023-2034)
• Africa Nutrigenomics Market Size in USD million (2023-2034)
• South America Nutrigenomics Market Size in USD million (2023-2034)

Nutrigenomics Market Recent Industry Trends and Milestones (2023-2026)

Nutrigenomics Market Startup Funding and Investment Trends

Investment in the nutrigenomics field has concentrated on technologies and business models that integrate genetic testing with digital health platforms and address the consumer trust challenges that have affected the broader direct-to-consumer genetic testing sector, namely AI-driven personalization software, digital health platform integration, and healthcare professional-oriented testing panels with strong scientific validation. Because the sector's largest historical consumer genomics platform, 23andMe, underwent a significant restructuring in 2025, investors and strategic acquirers have increasingly favored companies that combine genetic testing with established digital health infrastructure or that serve healthcare professional channels with stronger scientific credibility than direct-to-consumer-only models. The table below summarizes representative companies advancing nutrigenomics innovation.

Capital formation in this field is shaped by the restructuring of 23andMe and broader consumer trust considerations affecting direct-to-consumer genetic testing, so investors have favored companies that introduce differentiated healthcare professional-oriented testing panels, digital health platform integration, or specialized clinical application focus that serves defined needs or that a larger digital health or genomics company can acquire. Healthcare professional-oriented testing panels with strong scientific validation are a clear thesis, exemplified by Nutrigenomix. Digital health platform integration constitutes a second thesis, exemplified by Lifesum's acquisition of LYKON, and consumer whole genome sequencing services a third, exemplified by ProPhase Labs' DNA Complete subsidiary. The archetypal outcome is acquisition by a larger digital health or consumer wellness company seeking to add genetic testing capability, exemplified by Lifesum's acquisition of LYKON, or continued operation under restructured ownership, as with TTAM Research Institute's stewardship of 23andMe. The principal risks are continued consumer trust and data privacy concerns following high-profile industry incidents, the incomplete scientific evidence base linking some genetic variants to actionable dietary recommendations, and the dependence on continued consumer and healthcare provider awareness growth to sustain demand.

Key Takeaways from the Nutrigenomics Market Report Study

• Market size analysis for the current nutrigenomics market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product and technology developments, mergers, acquisitions, partnerships, and restructuring events that happened over the last 3 years.
• Key companies dominating the global nutrigenomics market.
• Various opportunities available for competitors in the nutrigenomics market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current nutrigenomics market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for nutrigenomics market growth in the future?

Target audience who can benefit from this nutrigenomics market report study

• Nutrigenomics testing and digital health platform providers
• Research organizations and consulting companies
• Nutrition, genomics, and preventive healthcare-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and partners dealing in nutrigenomics products and services
• Various end-users who want to know more about the nutrigenomics market and the latest technological developments in the nutrigenomics market.